Protein kinase C-β II expression in diffuse large B-cell lymphoma predicts for inferior outcome of anthracycline-based chemotherapy with and without rituximab

被引：13

作者：

Chaiwatanatorn, Kritika ^{[1
,2
]}

Stamaratis, Georgia ^{[3
]}

Opeskin, Ken ^{[3
]}

Firkin, Frank ^{[1
,2
]}

Nandurkar, Harshal ^{[1
,2
]}

机构：

[1] St Vincents Hosp, Dept Haematol, Melbourne, Vic, Australia

[2] St Vincents Hosp, Dept Med, Melbourne, Vic, Australia

[3] St Vincents Hosp, Dept Anat Pathol, Melbourne, Vic, Australia

来源：

LEUKEMIA & LYMPHOMA | 2009年 / 50卷 / 10期

基金：

澳大利亚国家健康与医学研究理事会;

关键词：

Protein kinase C-beta; diffuse large B-cell lymphoma; prognostic indicator; chemotherapy; rituximab; PKC-BETA; R-CHOP; PROGNOSTIC IMPACT; ELDERLY-PATIENTS; SURVIVAL; CLASSIFICATION; ACTIVATION; DEFICIENT;

D O I：

10.1080/10428190903165233

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Protein kinase C-beta II (PKC-beta II) expression has been reported to indicate inferior prognosis in diffuse large B-cell lymphoma (DLBCL) treated with anthracycline-based chemotherapy. This study compared prognostic significance of immunohistochemically determined PKC-beta II expression in de novo DLBCL treated with cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) chemotherapy with and without rituximab. Outcomes were assessed in 80 consecutive patients, 48 treated with CHOP, and 32 with rituximab plus CHOP (R-CHOP). PKC-beta II expression correlated with inferior overall survival (OS) and progression-free survival (PFS) in CHOP-treated patients with low-risk International Prognostic Index (IPI) disease (0-2 adverse factors), but not in the overall patient group unstratified by IPI. PKC-beta II expression correlated with inferior OS and PFS in R-CHOP-treated patients unstratified by IPI status. Immunohistochemically demonstrated PKC-beta II expression thus identified patient subgroups where alternative treatment strategies may confer superior outcome. We now report that PKC-beta II expression has prognostic significance not only for CHOP therapy in low-risk IPI disease, but also for all patients receiving CHOP plus rituximab.

引用

页码：1666 / 1675

页数：10

共 28 条

[1] Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling [J].

Alizadeh, AA ;

Eisen, MB ;

Davis, RE ;

Ma, C ;

Lossos, IS ;

Rosenwald, A ;

Boldrick, JG ;

Sabet, H ;

Tran, T ;

Yu, X ;

Powell, JI ;

Yang, LM ;

Marti, GE ;

Moore, T ;

Hudson, J ;

Lu, LS ;

Lewis, DB ;

Tibshirani, R ;

Sherlock, G ;

Chan, WC ;

Greiner, TC ;

Weisenburger, DD ;

Armitage, JO ;

Warnke, R ;

Levy, R ;

Wilson, W ;

Grever, MR ;

Byrd, JC ;

Botstein, D ;

Brown, PO ;

Staudt, LM .

NATURE, 2000, 403 (6769) :503-511

[2]

CLEMENS MJ, 1992, J CELL SCI, V103, P881

[3] Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma [J].

Colomo, L ;

Löpez-Guillermo, A ;

Perales, M ;

Rives, S ;

Martínez, A ;

Bosch, F ;

Colomer, D ;

Falini, B ;

Montserrat, E ;

Campo, E .

BLOOD, 2003, 101 (01) :78-84

[4] Membrane PKC-beta 2 protein expression predicts for poor response to chemotherapy and survival in patients with diffuse large B-cell lymphoma [J].

Espinosa, Inigo ;

Briones, Javier ;

Bordes, Ramon ;

Brunet, Salut ;

Martino, Rodrigo ;

Sureda, Ana ;

Prat, Jaime ;

Sierra, Jorge .

ANNALS OF HEMATOLOGY, 2006, 85 (09) :597-603

[5] Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma:: A study by the groupe d'Etude des lymphomes de l'adulte [J].

Feugier, P ;

Van Hoof, A ;

Sebban, C ;

Solal-Celigny, P ;

Bouabdallah, R ;

Fermé, C ;

Christian, B ;

Lepage, E ;

Tilly, H ;

Morschhauser, F ;

Gaulard, P ;

Salles, G ;

Bosly, A ;

Gisselbrecht, C ;

Reyes, F ;

Coiffier, B .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (18) :4117-4126

[6] Protein expression and cellular localization in two prognostic subgroups of diffuse large B-cell lymphoma:: Higher expression of ZAP70 and PKC-β II in the non-germinal center group and poor survival in patients deficient in nuclear PTEN [J].

Fridberg, Marie ;

Servin, Anna ;

Anagnostaki, Lola ;

Linderoth, Johan ;

Berglund, Mattias ;

Soderberg, Ola ;

Enblad, Gunilla ;

Rosen, Anders ;

Mustelin, Tomas ;

Jerkeman, Mats ;

Persson, Jenny L. ;

Wingren, Anette Gjorloff .

LEUKEMIA & LYMPHOMA, 2007, 48 (11) :2221-2232

[7] Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma [J].

Habermann, Thomas M. ;

Weller, Edie A. ;

Morrison, Vicki A. ;

Gascoyne, Randy D. ;

Cassileth, Peter A. ;

Cohn, Jeffrey B. ;

Dakhil, Shaker R. ;

Woda, Bruce ;

Fisher, Richard I. ;

Peterson, Bruce A. ;

Horning, Sandra J. .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (19) :3121-3127

[8] Expression of PKC-beta or cyclin D2 predicts for inferior survival in diffuse large B-cell lymphoma [J].

Hans, CP ;

Weisenburger, DD ;

Greiner, TC ;

Chan, WC ;

Aoun, P ;

Cochran, GT ;

Pan, ZG ;

Smith, LM ;

Lynch, JC ;

Bociek, RG ;

Bierman, PJ ;

Vose, JM ;

Armitage, JO .

MODERN PATHOLOGY, 2005, 18 (10) :1377-1384

[9] Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray [J].

Hans, CP ;

Weisenburger, DD ;

Greiner, TC ;

Gascoyne, RD ;

Delabie, J ;

Ott, G ;

Müller-Hermelink, HK ;

Campo, E ;

Braziel, RM ;

Jaffe, ES ;

Pan, ZG ;

Farinha, P ;

Smith, LM ;

Falini, B ;

Banham, AH ;

Rosenwald, A ;

Staudt, LM ;

Connors, JM ;

Armitage, JO ;

Chan, WC .

BLOOD, 2004, 103 (01) :275-282

[10]

HARRIS NL, 1994, BLOOD, V84, P1361

← 1 2 3 →